

Use of *Apretude* in Patients Who Have Had Buttock Implants, Dermal Fillers, or Autologous Fat Transfer

Summary

- There are no data available on the use of *Apretude* (long-acting cabotegravir [CAB LA]) for pre-exposure prophylaxis in patients who have had buttock implants, dermal fillers, or autologous fat transfer.
- In HPTN 083, subjects were excluded if they had surgically-placed or injected buttock implants or fillers, per self-report.^{1,2}
- In the product label there is no restriction on the use of CAB LA in patients with buttock implants or fillers.³
 - Clinicians should assess the anatomical position of the implants, fillers, or transferred fat, and use their judgement to determine whether CAB LA is appropriate for the patient.
- A phase 1 open-label trial, which evaluated the pharmacokinetics of a single dose of CAB LA administered into the *vastus lateralis* (thigh) muscle of the leg, showed a similar pharmacokinetic and safety profile compared with gluteal administration, warranting further evaluation for a potential alternative site of administration.⁴
- The dosing kit for CAB LA includes a standard 1.5-inch safety needle. If a 2-inch safety needle is required to reach the gluteus muscle, please visit the following website:
 - <http://www.fisherhealthcare.com/2inchsafetyneedle>
- Important Safety Information and Boxed Warning can be found in the [Prescribing Information](#) and can also be accessed from the [Our HIV Medicines](#) section of viihealthcare.com/us.

To access additional scientific information related to ViiV Healthcare medicines, visit the ViiV US Medical Portal at viihcmmedinfo.com.



Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

This information is scientific and non-promotional in nature and is not intended for further distribution.

This information is not intended to offer recommendations for using this product in a manner inconsistent with its approved labeling. Please consult the Prescribing Information. For ViiV Healthcare to monitor the safety of our products, we encourage healthcare professionals to report adverse events or suspected overdoses to the company at 877-844-8872.

Selection of references follows principles of evidence-based medicine and, therefore, references may not be all inclusive.



REFERENCES

1. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. *N Engl J Med*. 2021;385(7):595-608. doi:<http://dx.doi.org/10.1056/NEJMoa2101016>.
2. NCT02720094 (HPTN 083). Available at: <https://clinicaltrials.gov/ct2/show/NCT02720094?term=cabotegravir+prep&rank=1>. Accessed May 2, 2024.
3. ViiV Healthcare. Global Data Sheet for Cabotegravir (PrEP). Version 05. February 19, 2024.
4. Han K, Gevorkyan H, Sadik Shaik J, et al. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants. *Antimicrob Agents Chemother*. 2024;68(1):e0078123. doi:<http://dx.doi.org/10.1128/aac.00781-23>.